PULM

Pulmatrix Inc

PULM, USA

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

https://www.pulmatrix.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PULM
stock
PULM

Published on: 2025-12-11 15:05:16 earlytimes.in

Read more →
PULM
stock
PULM

Insider Sell: Will VNOL stock outperform global peers - 2025 Sector Review & Expert-Curated Trade Recommendations moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.06

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-18.53 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-17.60 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.05

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 11.82% of the total shares of Pulmatrix Inc

1.

Renaissance Technologies Corp

(3.0343%)

since

2025/06/30

2.

SBI Securities Co Ltd

(1.6583%)

since

2025/06/30

3.

BlackRock Inc

(1.5151%)

since

2025/06/30

4.

Vanguard Group Inc

(1.2871%)

since

2025/06/30

5.

Geode Capital Management, LLC

(1.1249%)

since

2025/06/30

6.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8842%)

since

2025/07/31

7.

Fidelity Extended Market Index

(0.5453%)

since

2025/07/31

8.

State Street Corp

(0.3818%)

since

2025/06/30

9.

UBS Group AG

(0.1496%)

since

2025/06/30

10.

Fidelity Series Total Market Index

(0.147%)

since

2025/07/31

11.

Fidelity Nasdaq Composite Index

(0.1251%)

since

2025/07/31

12.

Spartan Extended Market Index Pool F

(0.1238%)

since

2025/07/31

13.

Fidelity Total Market Index

(0.1219%)

since

2025/07/31

14.

Northern Trust Extended Eq Market Idx

(0.1193%)

since

2025/06/30

15.

NT Ext Equity Mkt Idx Fd - L

(0.1193%)

since

2025/06/30

16.

NT Ext Equity Mkt Idx Fd - NL

(0.0778%)

since

2025/06/30

17.

Dimensional US Core Equity 2 ETF

(0.07%)

since

2025/08/29

18.

Spartan Total Market Index Pool G

(0.0607%)

since

2025/07/31

19.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0605%)

since

2025/06/30

20.

Dimensional US Core Equity 1 ETF

(0.0384%)

since

2025/08/29

21.

DFA US Core Equity 2 I

(0.0383%)

since

2025/07/31

22.

DFA US Core Equity Class F

(0.0372%)

since

2025/06/30

23.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0337%)

since

2025/06/30

24.

Dimensional US Sustainability Core 1 ETF

(0.0257%)

since

2025/08/29

25.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0152%)

since

2024/12/31

26.

Tower Research Capital LLC

(0.0112%)

since

2025/06/30

27.

Northern Trust Wilshire 5000

(0.0041%)

since

2025/06/30

28.

Citigroup Inc

(0.0025%)

since

2025/06/30

29.

State St US Extended Mkt Indx NL Cl C

(0.0018%)

since

2025/08/31

30.

Bank of America Corp

(0.001%)

since

2025/06/30

31.

Hanson Mcclain Inc

(0.0001%)

since

2025/06/30

32.

JONES FINANCIAL COMPANIES LLLP

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.24

EPS Estimate

0

EPS Difference

-0.24

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.